MDS Global Launches an AI-powered Marketing Decision Intelligence Platform “MDS DecisionAI” That Enables Telcos to Reduce Churn and Increase Revenues
31.5.2023 09:22:00 EEST | Business Wire | Press release
Today, MDS Global, a leading provider of converged B2B/B2C billing and BSS solutions, has launched MDS DecisionAI, a new marketing decision intelligence platform that leverages the power of artificial intelligence to provide the critical insight ambitious MNOs, MVNOs, sub-brands and fixed line operators need to grow and outperform the competition.
MDS DecisionAI provides a full suite of telecoms specific AI modules including forecasting, churn, propensity models, and marketing and media mix analysis, that will help brands to optimise their marketing and commercial strategy. It enables them to identify monetisation opportunities and blind spots so they can make interventions sooner.
As a result, operators will be able to maximise yield and revenue, for example by predicting churn and identifying a customer’s propensity to consider other products offered in a cross-sell campaign, or through better-informed proposition development.
As part of MDS Global’s commitment to driving profitable digital telcos, MDS DecisionAI’s SaaS model, makes it a highly flexible and affordable way to operationally deploy AI. This is particularly beneficial for operators, MVNOs and sub brands who haven’t been able to invest in AI in the past due to the complexity of implementation, high integration costs and lack of affordable expert skill. The model eliminates the need for complex, costly and lengthy implementation projects. Instead, it can be easily integrated into existing billing, CVM and digital channels, no matter the platform used. Operators can expect to be set up and reaping the benefits of making more informed strategic decisions within 60 days.
Decision intelligence tools are changing the shape of telecoms with reports of cases where operators have made multi-million-pound revenue improvements from a more reactive churn response, seen 25% increase on cross sell success rates, and 30% uplift in acquisition by reviewing marketing media spend.
John Burton, CEO of MDS Global, says MDS DecisionAI will democratise artificial intelligence and decision intelligence, and make it accessible to all, including small brands: “Only 5%1 of telcos have a full AI marketing and personalisation strategy that is delivering an ROI on expected growth and benefits. MDS DecisionAI is a game changer and makes the vision of becoming a profitable digital telco more achievable.”
“Using MDS DecisionAI will create more agile and successful operators almost overnight. The use of AI will help them make the right commercial and marketing spending decisions and make more informed decisions about when and how to adjust their strategy or invest in innovation.”
More information about how AI is changing the telco landscape and supporting digital telco strategies is available here. Operators can also request a demo here.
About MDS Global
MDS Global is a leading provider of converged B2B/B2C billing and BSS solutions to MNOs, MVNOs, MVNEs and fixed line telcos. We power our customers’ transition from connectivity providers to digital service providers with carrier-grade solutions that include our cloud monetisation platform, AI-powered marketing decision intelligence platform, eSIM, and self-care apps portals.
Our agile “No code” SaaS solutions enable communications service providers to drive profit growth, deliver delightful digital customer experiences and launch innovative services fast.
To find out more, visit www.mdsglobal.com or follow us on LinkedIn and Twitter .
1 Unlocking the value of personalization at scale for operators, McKinsey, February 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005875/en/
Contact information
MDS Global press contact
Corine Suscens
Head of Global Marketing
marketing@mdsglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom